Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine types 1 and 3 (human diploid cell)
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The bivalent oral poliovirus vaccine types 1 and 3 (human diploid cell) is a live attenuated vaccine developed by Beijing Tiantan Biological Products for the prevention of poliomyelitis. It contains attenuated Sabin strains of poliovirus Type 1 and Type 3, which are propagated in human diploid cells. This formulation was designed to support the global initiative to eradicate polio by replacing the trivalent oral poliovirus vaccine (tOPV) with a bivalent version, thereby eliminating the type 2 component associated with vaccine-derived paralytic polio. The vaccine works by inducing a mucosal and systemic immune response against poliovirus types 1 and 3. It has been evaluated in Phase 3 clinical trials in China to establish its safety and immunogenicity, particularly in sequential schedules with inactivated poliovirus vaccines (IPV).
- Other names
- bOPVPoliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oralbivalent oral poliovirus vaccine types 1 and 3 human diploid cell
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine types 1 and 3 (human diploid cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine types 1 and 3 (human diploid cell).